Navigation Links
Amylin Pharmaceuticals Reports Third Quarter Financial Results
Date:10/20/2009

s was $22.4 million for the quarter ended September 30, 2009 compared to $58.7 million for the same period in 2008. Net loss for the quarter ended September 30, 2009 was $26.7 million, or $0.19 per share, compared to $79.0 million, or $0.58 per share, for the same period in 2008.

"The third quarter was one of strong operational and financial results and positions us well for long-term growth," said Daniel M. Bradbury, president and chief executive officer at Amylin Pharmaceuticals. "We continue to execute on our growth strategy by making progress against our long-term commercial plans, maximizing the potential of our clinical programs and advancing our pipeline."

Third Quarter Highlights

Highlights of Amylin's third quarter and recent activities include:

Corporate

  • Improved non-GAAP operating loss by 64% in the first nine months of 2009 compared to the same period in 2008
  • Entered a Global Development and Commercialization Agreement with Biocon Limited for a novel peptide hybrid
  • Announced Paulo F. Costa as Amylin's Chairman of the Board

Exenatide

  • Received the Day 74 letter from the U.S. Food and Drug Administration (FDA) and submitted the 120 day safety update for exenatide once weekly
  • Presented data from more than 20 studies, with partner Eli Lilly and Company, at the Annual Meeting of the European Association for the Study of Diabetes (EASD). Data presented were the latest research findings on BYETTA and exenatide once weekly

Nine Months Ended September 30, 2009

Total revenues for the nine months ended September 30, 2009 were $614.3 million. This includes net product sales of $569.7 million, including $503.9 million for BYETTA and $65.8 million for SYMLIN. This compares to net product sales of $580.4 million, consisting of $515.9 million for BYETTA and $64.5 million for SYMLIN for the same period in
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity
2. Amylin Pharmaceuticals to Present Novel Data on Promising Obesity Pipeline at 2008 Annual Scientific Meeting of The Obesity Society
3. Amylin and Lilly Announce Plans to Develop Pen Device for Exenatide Once Weekly
4. Amylin Pharmaceuticals Highlights New Data Supporting Therapeutic Potential of Obesity Pipeline at Obesity 2009
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is pleased ... of the first-of-its-kind comic book available in Canada ... been designed specifically to educate children and their parents about ... affecting more than 300,000 Canadians. Eisai is guided ... (hhc) , in which the patient is central – there ...
(Date:8/21/2014)... Aug. 21, 2014 /PRNewswire-iReach/ -- Inc. ... for the third straight year, No. 349 in ... exclusive ranking of the nation,s fastest-growing private companies. ... the most important segment of the economy—America,s independent ... Domino,s Pizza, LinkedIn, Zillow, and many other well-known ...
(Date:8/21/2014)... Aug. 21, 2014  Seventy-one percent of Americans believe the ... a serious public health and safety issue in ... survey released today by Repass & Partners, a ... "Americans understand the severity of the prescription medication abuse problem ... this very serious health situation facing our country," Rex ...
Breaking Medicine Technology:Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3Consumers Desperate For Measures To Curb Prescription Drug Abuse 2Consumers Desperate For Measures To Curb Prescription Drug Abuse 3
... thinking about cosmetic surgery, your first stop should be at ...   SculptMyDream.com is the first website to let individuals ... photography.  Not only will this help you "Sculpt YOUR dream", ... that dream into reality. (Photo:   http://photos.prnewswire.com/prnh/20110720/NY38494 ...
... 20, 2011 Landacorp , A Carewise Health ... solutions, today announced that its CareRadius Suite has been ... Coventry Health Care is a diversified national ... plans that serve more than five million members across ...
Cached Medicine Technology:See the Results of Your Breast Augmentation, Before Surgery 2Coventry Health Care Selects Landacorp's CareRadius Suite to Advance Collaborative Care 2
(Date:8/21/2014)... DoudouneCanadienneGoosePasCher.fr, one of the most popular suppliers ... its new selection of Trillium Parkas for 2014. Moreover, ... these fashionable and comfortable items are available at discounted ... last until September 01. , The CEO says ... Canada Goose Trillium Parkas for new and old ...
(Date:8/21/2014)... is an internationally well-known supplier and leader in the ... collection of elegant bamboo floorings . These new ... for high quality floorings for their own houses. Now, ... to 29 percent off). Before the end of August, ... The company’s bamboo flooring products are made using unique, ...
(Date:8/21/2014)... Mich. Using heart-lung support technology, the University of ... of kidneys, livers and pancreases available for transplant by ... the journal Transplantation and detail the impact ... Oxygenation, or ECMO, to improve the quality and viability ... "Organ transplant is limited by the number of donated ...
(Date:8/21/2014)... 2014 Improv performers from Fun House ... dementia at Silverado Turtle Creek memory care community in ... entertainers ranging from ages 10 to 16, delivers a ... 40-minute set. The troupe's philosophy is that improv is ... them to touch audiences regardless of their circumstance — ...
(Date:8/21/2014)... 21, 2014 (HealthDay News) -- Black mothers are less ... here,s one possible reason why: Hospitals in neighborhoods with ... those in areas with more white residents, a U.S. ... are much less common in medical centers where the ... U.S. Centers for Disease Control and Prevention reported Thursday. ...
Breaking Medicine News(10 mins):Health News:Fashionable And Comfortable Canada Goose Trillium Parkas For Sale At DoudouneCanadienneGoosePasCher.fr 2Health News:Buy Elegant Bamboo Floorings from Internationally Well-known Supplier BambooIndustry.com 2Health News:Extracorporeal support can significantly increase number of organs for transplant 2Health News:Unicorn Clearance Improv Troupe Brings Laughter to Residents with Dementia at Silverado Memory Care 2Health News:Racial Disparities in Breast-Feeding May Start With Hospitals, Study Suggests 2
... , , HATBORO, Pa., Aug. 13 InfoLogix, Inc. ... solutions for the healthcare and commercial industries, today announced financial results for ... (Logo: http://www.newscom.com/cgi-bin/prnh/20090618/NE3513 5 LOGO ... , , David T. Gulian, president and chief ...
... , , , BRISTOL, ... KG ) today announced that the U.S. Food and Drug ... Extended Release Capsules for oral use, a long-acting Schedule II ... when a continuous, around-the-clock opioid analgesic is needed for an ...
... , , REDWOOD ... ) today reported financial results and corporate progress for its fiscal ... , "With a slower than expected rate of ... quarter we had to make difficult decisions to revise our direct ...
... , , IRVINE, Calif., ... of surgical products used in the treatment of patients suffering from ... June 30, 2009. , , Net revenues in ... the prior year second quarter net revenues of $4,119,000. The ...
... rise if organ comes from deceased man, study finds, , ... donated organ came from a deceased male face an increased ... Canadian researchers have found. , The risk is short-term, though, ... researchers said. Their study found that the risk goes ...
... Genetic mutation could explain why some function fine on six hours ... few can get by just fine on six hours of sleep, ... why. , The finding doesn,t appear likely to help people with ... people sleep as long as they do, said study co-author Ying-Hui ...
Cached Medicine News:Health News:InfoLogix Announces Second Quarter Financial Results 2Health News:InfoLogix Announces Second Quarter Financial Results 3Health News:InfoLogix Announces Second Quarter Financial Results 4Health News:InfoLogix Announces Second Quarter Financial Results 5Health News:InfoLogix Announces Second Quarter Financial Results 6Health News:InfoLogix Announces Second Quarter Financial Results 7Health News:InfoLogix Announces Second Quarter Financial Results 8Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 2Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 3Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 4Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 5Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 6Health News:Video: FDA Approves EMBEDA(TM) For Management of Moderate to Severe Chronic Pain 7Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 2Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 3Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 4Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 5Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 6Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 7Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 8Health News:Cardica Announces Fiscal 2009 Fourth Quarter and Year End Financial Results 9Health News:Cardiogenesis Reports Second Quarter 2009 Results 2Health News:Cardiogenesis Reports Second Quarter 2009 Results 3Health News:Cardiogenesis Reports Second Quarter 2009 Results 4Health News:Cardiogenesis Reports Second Quarter 2009 Results 5Health News:Cardiogenesis Reports Second Quarter 2009 Results 6Health News:Cardiogenesis Reports Second Quarter 2009 Results 7Health News:Kidney Donor's Sex Could Affect Women's Outcomes 2Health News:They Snooze Less, But They Don't Lose 2
High intensity halogen lamp with built-in, switchable spare. Optical light concentrator to optimize existing light energy....
... AlphaCor is a biocompatible, flexible, one-piece artificial ... or diseased native cornea., ,The World Health ... more than 10 million people worldwide, however ... year. This shortfall is due to a ...
PDA-version of the complete ICD-9 diagnosis codes....
PDA formatted guide containing outlines and detailed information on the diagnosis and treatment of HIV infection and AIDS....
Medicine Products: